Our lab interested in using polymer-based nanomedicine to promote scientific knowledge in cancer treatment. Preclinical protocols spanning from test-tube evaluation to animal models will provide the proof of principal for any future approaches.
Our lab integrates nanotechnology, imaging science, gene therapy and cancer biology. Based on pharmaceutical sciences, we provide solutions on drug delivery using modern or more traditional approaches, in order to improve pharmacokinetic, biodistribution and absorption, water solubility and efficacy for smaller and bigger molecules. We expand to mechanistic studies of compounds and nucleic acids, for gene regulation and treatment on a panel of diseases.
With thousands of compounds in the preclinical pipeline, most of them limited by high lipophilicity, rapid elimination/metabolism, low absorption or unfavorable biodistribution profiles, we apply drug delivery methodology using dosage formulation techniques and nanotechology. While targeted delivery is steadily being recognized as a key ingredient for successfully delivering molecules to the desired tissue and cell, the possible applications have exponentially increased.
Our current primary focus is the delivery of nucleic acids using lipid-based nanocarriers for the treatment of lung cancer.
Education: Ph.D. in pharmaceutical technology/sciences
Selected Publications
Hossian AKMN, Mackenzie GGM, and Mattheolabakis G, Combination of miR-143 and miR-506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclin-dependent kinases, Oncology Reports, 2021;45(4):2.doi: 10.3892/or.2021.7953.
Hossian A, Sajib M, Tullar P, Mikelis C, Karen Briski, Mattheolabakis G, Analysis of combinatorial miR treatments to regulate Cell Cycle and Angiogenesis, Accepted – JoVE, 2019, (145), e59460, doi:10.3791/59460
Hossian A, Sajib M, Tullar P, Mikelis C, Mattheolabakis G, Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancercell cycle progression and angiogenesis in vitro, Scientific Reports, 2018,doi: 10.1038/s41598-018-28872-2
Hossian A, Zahra FT, Poudel S, Abshire CF, Polk P, Garai J, ZabaletaJ, Mikelis CM, Mattheolabakis G, Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance. Sci Rep. 2021;11(1):6520.Epub 2021/03/24. doi: 10.1038/s41598-021-85930-y. PubMed PMID: 33753779; PMCID:PMC7985311
Hossian A, Jois SD, Jonnalagadda SC, Mattheolabakis G. Nucleic Acid Delivery with alpha-Tocopherol-Polyethyleneimine-Polyethylene Glycol Nanocarrier System. Int J Nanomedicine. 2020;15:6689-703. Epub 2020/09/29. doi:10.2147/IJN.S259724. PubMed PMID: 32982227; PMCID: PMC7494428.
Caceres J, Munoz-Sagastibelza M, Hossian A, Paredes J, BarreraK, Mattheolabakis G, Martello LA, Vignesh S. Evaluation of the feasibility of intrapancreatic delivery of drug-loaded microparticles via EUS-guided fineneedle injection using a swine model. Endosc Int Open. 2019;7(8):E1008-E17.Epub 2019/08/14. doi: 10.1055/a-0953-2070. PubMed PMID: 31404394; PMCID:PMC6687482.
Shrestha A, Lahooti B, Mikelis C, Mattheolabakis G, Chlorotoxin and Lung Cancer: A Targeting Perspective for Drug Delivery, Pharmaceutics, 2022Nov 26. doi: 10.3390/pharmaceutics14122613, PMID: 36559106
Singh A, Xu J, Mattheolabakis G, Amiji M, EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model, Nanomedicine: nanotechnology, biology, and medicine.2016; 12(3):589-600. NIHMSID: NIHMS742587
Keywords: nanocarriers, lung cancer, drug delivery
